Hansoh Pharmaceutical Group Company Limited (03692.HK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	29.0B	15.0B	12.3B	10.1B	9.4B
Cost of Revenue	2.7B	1.5B	1.1B	1.0B	870.2M
Gross Profit	26.3B	13.5B	11.2B	9.1B	8.5B
Operating Expenses
R&D Expense	6.6B	3.4B	2.7B	2.1B	1.7B
SG&A Expense	9.4B	4.7B	4.5B	4.2B	4.1B
General & Admin Expense	1.4B	671.7M	712.5M	709.8M	597.5M
Selling & Marketing Expense	8.0B	4.1B	3.8B	3.5B	3.6B
Other Expenses	(44.4M)	—	(85.8M)	(104.4M)	(3.8M)
Total Operating Expenses	15.9B	8.1B	7.1B	6.2B	5.8B
Cost and Expenses	18.6B	9.6B	8.2B	7.3B	6.7B
Operating Income (EBIT)	10.4B	5.4B	4.0B	2.8B	2.7B
Non-Operating
Interest Income	2.9B	1.1B	995.3M	905.0M	309.1M
Interest Expense	49.4M	3.2M	6.7M	66.7M	58.1M
Net Interest Income	2.9B	1.1B	988.6M	838.3M	250.9M
Other Non-Op Income/Expense	3.1B	1.1B	1.1B	926.8M	277.2M
Non-Operating Income (excl Interest)	31.7M	14.3M	129.0M	(993.5M)	63.7M
EBT (Pre-Tax Income)	13.5B	6.6B	5.1B	3.8B	2.9B
Income Tax Expense	2.1B	995.1M	713.4M	488.7M	364.7M
Bottom Line
Net Income	11.4B	5.6B	4.4B	3.3B	2.6B
Earnings from Cont. Ops	11.5B	5.6B	4.4B	3.3B	2.6B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	11.4B	5.6B	4.4B	3.1B	2.6B
Per Share
Basic EPS	HK$1.91	HK$0.93	HK$0.74	HK$0.52	HK$0.44
Diluted EPS	HK$1.90	HK$0.93	HK$0.73	HK$0.52	HK$0.44
Revenue Per Share	HK$4.78	HK$2.51	HK$2.07	HK$1.68	HK$1.59
Shares
Basic Shares Outstanding	6.1B	6.0B	5.9B	6.0B	5.9B
Diluted Shares Outstanding	6.1B	6.0B	5.9B	6.0B	5.9B
Profitability Metrics
EBITDA	11.1B	5.8B	4.3B	4.2B	2.9B
D&A	703.8M	364.4M	375.6M	366.4M	324.4M
EBIT	10.4B	5.4B	3.9B	3.8B	2.6B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026